Merck KGaA (BIT:1MRK)
Italy · Delayed Price · Currency is EUR | Market Cap | 61.09B +25.8% |
| Revenue (ttm) | 20.96B -1.7% |
| Net Income | 2.53B -10.2% |
| EPS | 5.83 -10.0% |
| Shares Out | n/a |
| PE Ratio | 24.12 |
| Forward PE | 17.23 |
| Dividend | 2.20 (1.51%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 85 |
| Open | 141.70 |
| Previous Close | 142.60 |
| Day's Range | 141.70 - 142.40 |
| 52-Week Range | 102.35 - 148.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Financial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial StatementsNews
GordonMD Global Investments: Cyllene Therapeutics Raises €33 Million Series C
Financing co-led by GordonMD Global Investments and Merck Ventures B.V. (an affiliate of Merck KGaA, Darmstadt Germany) with participation from new and existing investors Company Rebrands from EG ...
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02.07.2...
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer
On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.
Healthcare M&A Activity Surges, Merck KGaA (MKGAF) Acquires Bio-Techne (TECH)
Healthcare M&A Activity Surges, Merck KGaA (MKGAF) Acquires Bio-Techne (TECH)
Merck KGaA (MKGAF) Acquires Bio-Techne (TECH) for $73 per Share
Merck KGaA (MKGAF) Acquires Bio-Techne (TECH) for $73 per Share
Bio-Techne Corporation (TECH) Announces Merger Agreement with Merck KGaA
Bio-Techne Corporation (TECH) Announces Merger Agreement with Merck KGaA
Bio-Techne To Be Acquired By Merck In $11.3 Bln Cash Deal
(RTTNews) - Bio-Techne Corp. (TECH), a commercial-stage biotechnology company headquartered in Minnesota, Thursday announced a definitive agreement to be acquired by Darmstadt, Germany-based Merck KGa...
Germany's Merck KGaA Swoops In With $11.3 Billion Medtech Buyout
Germany's Merck KGaA pledged Thursday to buy Bio-Techne for $11.3 billion. The deal expands its portfolio of life sciences tools.
Merck KGaA Transcript: M&A announcement
The acquisition of Bio-Techne for $73 per share aims to accelerate growth in Life Science by combining complementary portfolios, with EUR 140 million in cost synergies expected within three years. The deal is immediately margin accretive, enhances innovation, and strengthens U.S. presence.
Merck KGaA Slides: M&A announcement
Merck KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Merck KGaA Press release: M&A announcement
Merck KGaA issued a press release on June 25, 2026, disclosing material business information to investors.
Bio-Techne (TECH) Surges 22% on Merck KGaA Acquisition Offer
Bio-Techne (TECH) Surges 22% on Merck KGaA Acquisition Offer
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareho...
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Merck KGaA To Buy Bio-Techne For Around $11.3 Bln; TECH Up Over 23% In Pre-Market
(RTTNews) - Merck KGaA (MKKGY, MRCG.DE, MRK.DE), a German science and technology major, said on Thursday that it has inked a deal to buy Bio-Techne Corporation (TECH) for $73 per share in cash, or aro...
EQS-Adhoc: Merck KGaA: Merck Agrees to Acquire Bio-Techne Corporation
EQS-Ad-hoc: Merck KGaA / Key word(s): Mergers and Acquisitions / Merger Merck KGaA: Merck Agrees to Acquire Bio-Techne Corporation 25-Jun-2026 / 11:33 CET/CEST Disclosure of an inside information acc....
MilliporeSigma: Bio-Based Solvents Take Center Stage at CHEMUK
NORTHAMPTON, MA / ACCESS Newswire / June 23, 2026 / MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, took center stage at CHEMUK 2026 with the launch of ...
EMD Serono: Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need The collaboration wi...
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies.
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies.
Information Services Group, Inc.: ISG Event to Explore How Enterprises Are Turning AI Investments Into Measurable Business Value
Leaders from State Street, Pfizer, Siemens, Merck KGaA, Deutsche Bank, Fresenius, Hyundai Motor Europe, Union Investment and more to join ISG AI Impact Summit in Frankfurt Information Services Gro...
Merck KGaA
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.